公开(公告)号：US20130028971A1

公开(公告)日：2013-01-31

申请号：US13559013

申请日：2012-07-26

申请人： Giuseppe Claudio VISCOMI ,  Paola MAFFEI ,  Vittoria LAURO ,  Fiorella CALANNI ,  Beatrice VITALI ,  Federica CRUCIANI

发明人： Giuseppe Claudio VISCOMI ,  Paola MAFFEI ,  Vittoria LAURO ,  Fiorella CALANNI ,  Beatrice VITALI ,  Federica CRUCIANI

IPC分类号： A61K31/437 ,  A61P15/02 ,  A61P31/04 ,  A61K9/32

CPC分类号： A61K31/437 ,  A61K9/0034

摘要： The invention relates generally to pharmaceutical compositions comprising rifaximin effective at treating vaginal infections, and in particular bacterial vaginosis. The pharmaceutical compositions comprising rifaximin granules are characterized in that they release rifaximin in the vagina in a controlled way. The present invention also relates to processes for preparation of the rifaximin pharmaceutical compositions and their use in the treatment of vaginal infections. Effective dosages and courses of treatment useful and effective at recovering from the disease and preventing any possible relapse are also provided.

摘要翻译： 本发明一般涉及药物组合物，其包含有效治疗阴道感染，特别是细菌性阴道病的利福昔明。 包含利福昔明颗粒的药物组合物的特征在于它们以受控的方式释放阴道内的利福昔明。 本发明还涉及制备利福昔明药物组合物的方法及其在治疗阴道感染中的用途。 还提供了有效的剂量和治疗疗程，其有效和有效地从疾病中恢复并防止任何可能的复发。

公开(公告)号：US10258610B2

公开(公告)日：2019-04-16

申请号：US13559013

申请日：2012-07-26

申请人： Giuseppe Claudio Viscomi ,  Paola Maffei ,  Vittoria Lauro ,  Fiorella Calanni ,  Beatrice Vitali ,  Federica Cruciani

发明人： Giuseppe Claudio Viscomi ,  Paola Maffei ,  Vittoria Lauro ,  Fiorella Calanni ,  Beatrice Vitali ,  Federica Cruciani

IPC分类号： A61K31/437 ,  A61K9/00

摘要： The invention relates generally to pharmaceutical compositions comprising rifaximin effective at treating vaginal infections, and in particular bacterial vaginosis. The pharmaceutical compositions comprising rifaximin granules are characterized in that they release rifaximin in the vagina in a controlled way. The present invention also relates to processes for preparation of the rifaximin pharmaceutical compositions and their use in the treatment of vaginal infections. Effective dosages and courses of treatment useful and effective at recovering from the disease and preventing any possible relapse are also provided.